Pharmacy
The Food and Drug Administration July 10 released a proposed rule that would modernize drug establishment registration requirements, with implications for pharmaceutical manufacturers and health systems that depend on a stable medication supply chain.
On June 29, Sen. Bill Cassidy, R-La., unveiled a legislative discussion draft titled the 340B Drug Pricing Integrity and Affordability for Patients Act.
Reps. Scott Peters, D-Calif., and John Joyce, R-Pa., introduced the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act, or SECURE 340B Act.
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers.
John Pastor, president of Fairview Pharmacy Services and chief operating officer of Fairview Pharmacy Solutions, shares how M Health Fairview’s expansive pharmacy network, centralized services hub and integrated technology are reshaping medication access in Minnesota and beyond.
As pharmacy closures accelerate nationwide, M Health Fairview is proving what’s possible when a health system steps up.
The White House Oct. 10 announced it reached an agreement with AstraZeneca to align drug prices with the lowest paid by other developed nations, also known as the most-favored-nation price.
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations — what is known as the most-favored-nation, or MFN, price.
The Food and Drug Administration recently disclosed dozens of warning letters sent to drug companies that accuse them of using misleading or deceptive advertising.
President Trump Sept. 10 signed a memorandum directing the Department of Health and Human Services and Food and Drug Administration to require drug companies to include full safety warnings on their consumer advertisements.